Vaccinia Virus Extract Evaluation via BDNF Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of methods for determining or evaluating the action of extracts from inflamed tissues inoculated with vaccinia virus on BDNF expression and intracellular signaling pathways, which are crucial for assessing their pharmaceutical effects.
Innovation Solution
A method involving the use of cultured cells, such as SH-SY5Y cells, where the extract from inflamed tissues inoculated with vaccinia virus is treated to measure BDNF expression and activation of proteins in intracellular signaling pathways, utilizing inhibitors and specific antibodies to understand its pharmacological action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to determine or evaluate the extract from inflamed tissues, then the evaluation process is complex and time-consuming, but there is a lack of specific methods for assessing BDNF expression and intracellular signaling pathway actions
Solution Approach 1:
The patent introduces cultured cells as an intermediary system to evaluate the extract's action. The cells serve as a model system where BDNF expression and intracellular signaling pathway activations can be measured, providing a standardized and reproducible evaluation method that bridges the gap between complex tissue extracts and quantifiable biological responses
Solution Approach 2:
The patent measures specific parameters (BDNF expression levels and phosphorylation states of signaling proteins) to evaluate the extract's action. By focusing on these quantifiable parameters, the method transforms a complex qualitative assessment into a precise quantitative measurement system
2Reliability
If the extract's action on BDNF expression and signaling pathways is measured, then pharmaceutical effect can be guaranteed, but the measurement process requires multiple inhibitors and antibodies increasing operational complexity
Solution Approach 1:
The patent segments the evaluation process into distinct components: measuring BDNF expression separately from measuring intracellular signaling pathway activations. This segmentation allows each parameter to be assessed using specific, optimized protocols with appropriate inhibitors and antibodies, making the overall complex evaluation manageable and systematic
3Measurement precision
If a comprehensive evaluation method for the extract is developed, then measurement precision is improved, but the time and resources required for the evaluation increase
Solution Approach 1:
The patent employs cultured cells that are pre-prepared and can be maintained in culture, allowing for preliminary setup of the evaluation system. This enables multiple samples to be evaluated using the same cell line and protocol framework, reducing the time required for each individual evaluation while maintaining comprehensive measurement capabilities
Data Source
AI summary
An object of the present invention is to provide a method for determination or evaluation of an extract from inflamed tissues inoculated with vaccinia virus where the enhancement of activation of neurotrophic factor such as BDNF in cultured cells or the enhancement of activation of proteins participating therein is used as an indicator. The present invention relates to a novel method for determination or evaluation of an extract from inflamed tissues inoculated with vaccinia virus and relates to a method for determination or evaluation of the extract where the enhancement of production of neurotrophic factor such as BDNF in cultured cells or the enhancement of activation of various proteins in intracellular signaling pathway participating in production of BDNF, etc. is used as an indicator.